Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort

被引:14
作者
Tastaldi, Luciano [1 ]
Krpata, David M. [1 ]
Prabhu, Ajita S. [1 ]
Petro, Clayton C. [1 ]
Haskins, Ivy N. [1 ]
Perez, Arielle J. [1 ]
Alkhatib, Hemasat [1 ]
Colturato, Iago [4 ]
Tu, Chao [2 ]
Lichtin, Alan [3 ]
Rosen, Michael J. [1 ]
Rosenblatt, Steven [1 ]
机构
[1] Cleveland Clin Fdn, Comprehens Hernia Ctr, Digest Dis & Surg Inst, 9500 Euclid Ave,A-100, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Dept Hematol & Med Oncol, Taussig Canc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA
[4] Hosp Amaral Carvalho, Dept Hematol & Med Oncol, Jau, Brazil
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2019年 / 33卷 / 02期
关键词
Splenectomy; Laparoscopic splenectomy; Immune thrombocytopenia; ITP; PREDICTIVE FACTORS; DOUBLE-BLIND; PURPURA; ELTROMBOPAG; EFFICACY; SAFETY; ADULTS; STANDARDIZATION; ROMIPLOSTIM; MANAGEMENT;
D O I
10.1007/s00464-018-6321-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundThe advent of newer second-line medical therapies (SLMT) for immune thrombocytopenia (ITP) has contributed to decreased rates of splenectomy, following a trend to avoid or delay surgery. We aimed to characterize the long-term outcomes of laparoscopic splenectomy (LS) for ITP at our institution, examining differences in LS efficiency when performed before or after SLMTs.MethodsAdults with primary ITP who underwent LS between 2002 and 2016 were identified. Retrospective review of electronic medical records was supplemented with telephone interviews. Treatment response was defined according to current guidelines as complete responders (CR), responders (R), and non-responders (NR). Kaplan-Meier estimates assessed relapse-free rates, and predictors of long-term response were investigated using logistic regression.Results109 patients met inclusion criteria, from which 42% were treated with an SLMT before referral to LS. LS was completed in all cases, with no conversions or intraoperative complications. The perioperative morbidity was 7.3%, including 3 deep vein and 2 portal vein thrombosis, one reoperation for bleeding, and no mortalities. Splenectomy was initially effective in 99 patients (CR+R=90.8%), and 10 patients were NR. At a median 62-month follow-up, 25 patients relapsed, resulting in a 68% CR+R rate. Proportion of CR+R was similar in patients who previously received SLMT and those who did not (61 vs. 76.7%, p=0.08). CR+R patients were younger (45 vs. 53, p=0.03), had higher preoperative platelet counts (36 vs. 19, p=0.01), and experienced a higher increment in platelet counts during hospital stay (117 vs. 38, p<0.001) as well as 30-days postoperatively (329 vs. 124, p<0.001). Only a robust response in platelet count at 30-days postoperatively was independently associated with long-term response (OR 1.005, p=0.006).ConclusionLS was curative in 68% of patients, with no statistically significant difference when performed before or after SLMTs. Outcomes remain challenging to predict preoperatively, with only a robust increase in platelet counts on short term being associated with long-term response.
引用
收藏
页码:475 / 485
页数:11
相关论文
共 40 条
  • [1] True benefit or selection bias: an analysis of laparoscopic versus open splenectomy from the ACS-NSQIP
    Ahad, Sajida
    Gonczy, Chad
    Advani, Vriti
    Markwell, Stephen
    Hassan, Imran
    [J]. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2013, 27 (06): : 1865 - 1871
  • [2] Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children
    Ahmed, Rayaz
    Devasia, Anup J.
    Viswabandya, Auro
    Lakshmi, Kavitha M.
    Abraham, Aby
    Karl, Sampath
    Mathai, John
    Jacob, Paul M.
    Abraham, Deepak
    Srivastava, Alok
    Mathews, Vikram
    George, Biju
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (09) : 1429 - 1434
  • [3] Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
    Bussel, James B.
    Provan, Drew
    Shamsi, Tahir
    Cheng, Gregory
    Psaila, Bethan
    Kovaleva, Lidia
    Salama, Abdulgabar
    Jenkins, Julian M.
    Roychowdhury, Debasish
    Mayer, Bhabita
    Stone, Nicole
    Arning, Michael
    [J]. LANCET, 2009, 373 (9664) : 641 - 648
  • [4] Medical complications following splenectomy
    Buzele, R.
    Barbier, L.
    Sauvanet, A.
    Fantin, B.
    [J]. JOURNAL OF VISCERAL SURGERY, 2016, 153 (04) : 277 - 286
  • [5] Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
    Cheng, Gregory
    Saleh, Mansoor N.
    Marcher, Claus
    Vasey, Sandra
    Mayer, Bhabita
    Aivado, Manuel
    Arning, Michael
    Stone, Nicole L.
    Bussel, James B.
    [J]. LANCET, 2011, 377 (9763) : 393 - 402
  • [6] Medical progress: Immune thrombocytopenic purpura.
    Cines, DB
    Blanchette, VS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) : 995 - 1008
  • [7] Vascular complications after splenectomy for hematologic disorders
    Crary, Shelley E.
    Buchanan, George R.
    [J]. BLOOD, 2009, 114 (14) : 2861 - 2868
  • [8] Controversies in the treatment of immune thrombocytopenia
    Cuker, Adam
    Cines, Douglas B.
    Neunert, Cindy E.
    [J]. CURRENT OPINION IN HEMATOLOGY, 2016, 23 (05) : 479 - 485
  • [9] Managing uncontrolled postsplenectomy reactive thrombocytosis in idiopathic thrombocytopenic purpura: Role of thrombocytapheresis
    Das, Sudipta Sekhar
    Bhattacharya, Soumya
    Sen, Subrata
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (02) : 171 - 173
  • [10] How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
    Ghanima, Waleed
    Godeau, Bertrand
    Cines, Douglas B.
    Bussel, James B.
    [J]. BLOOD, 2012, 120 (05) : 960 - 969